Penicillin Allergy Testing and Resensitization Rate

Centre Hospitalier Régional Metz-Thionville

Status: Completed

Conditions: Penicillin Allergy

Treatments: Other: Behavioral allergy testing protocol

Study type: Observational

Funder types: Other

Identifiers

NCT03942731

2019-03Obs-CHRMT

Details and patient eligibility

About

Penicillin is one of the earliest discovered antibiotics and a drug of choice for several infections. Up to 10 to 20% of all patients in clinical trial are labeled as penicillin allergic. Most of these patients do not have a true allergy but few have had it verified. Approximately 80% of patients with IgE-mediated penicillin allergy lose their sensitivity after 10 years. Several studies have been conducted denying the risk of sensitization following negative testing of penicillin allergy. Investigators have not had the same experience and have therefore decided to conduct a retrospective study review of 83 adult outpatients with a distant penicillin allergy label and evaluate outcomes of skin retesting six weeks following Drug Provocation Test and challenge.

Enrollment: 83 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18 years old

Exclusion criteria

• Pregnancy
• poorly controlled asthma and cardiovascular disease
• use of drugs that interfere with testing and could not be stopped such as antihistamines, tricyclic antidepressants, antipsychotics, beta blockers, high dose oral glucocorticoids
• Non-IgE mediated type of serious allergic reaction such as Stevens - Johnson syndrome, Toxic Epidermal Necrolysis, and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome.

Trial design

83 participants in 1 patient group

Experimental

Description:

83 adult outpatients at CHR Metz-Thionville with penicillin allergy label

Treatment:

Other: Behavioral allergy testing protocol